Sunday, 9 August 2026Belfast · Northern Ireland

Retrospective archiveHistorical reports were compiled from linked contemporaneous sources. Dates refer to the events covered.How the archive works

Health31 May 2026Archive brief

Study published by The New England Journal of Medicine reports that the daraxonrasib, a RAS inhibitor drug that targets KRAS-mutated cancers

A study published by The New England Journal of Medicine reports that the daraxonrasib, a RAS inhibitor drug that targets KRAS-mutated cancers, has doubled median overall survival in patients with metastatic pancreatic cancer as compared to chemotherapy.

By Belfast Herald Newsdesk2 min read

Image not availableNo sufficiently relevant, reusable photograph is held for this archived report.

The development was among the significant health stories being followed from United Kingdom. Contemporary coverage attributed the principal details to NPR on 31 May 2026.

This report belongs to The Belfast Herald's retrospective archive. It was compiled from the cited reporting and preserves the information available on the date shown; later developments are covered separately.